Manifaxine
From Wikipedia, the free encyclopedia
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H15F2NO2 |
Molar mass | 243.254 g·mol−1 |
3D model (JSmol) | |
show
InChI
| |
NY (what is this?) |
Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, one of the major active metabolites[citation needed] of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications,[1][2] but no results have been reported following these initial trials and its current status is unclear.
See also[]
- Phenmetrazine
- Radafaxine
- Hydroxybupropion
- G-130
- 2-Phenyl-3,6-dimethylmorpholine
References[]
- ^ DeVeaugh-Geiss J, Conners CK, Sarkis EH, Winner PK, Ginsberg LD, Hemphill JM, et al. (August 2002). "GW320659 for the treatment of attention-deficit/hyperactivity disorder in children". Journal of the American Academy of Child and Adolescent Psychiatry. 41 (8): 914–20. doi:10.1097/00004583-200208000-00009. PMID 12162627.
- ^ Spraggs CF, Pillai SG, Dow D, Douglas C, McCarthy L, Manasco PK, et al. (December 2005). "Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects". Pharmacogenetics and Genomics. 15 (12): 883–9. doi:10.1097/01213011-200512000-00006. PMID 16272960. S2CID 40809351.
show
Stimulants | |
---|---|
Adamantanes |
|
Adenosine antagonists |
|
Alkylamines |
|
Ampakines | |
Arylcyclohexylamines |
|
Benzazepines |
|
Cathinones |
|
Cholinergics |
|
Convulsants |
|
Eugeroics |
|
Oxazolines |
|
Phenethylamines |
|
Phenylmorpholines |
|
Piperazines | |
Piperidines |
|
Pyrrolidines | |
Racetams |
|
Tropanes |
|
Tryptamines | |
Others |
|
ATC code: N06B |
show
Monoamine reuptake inhibitors | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DAT (DRIs) |
| ||||||||||||||
NET (NRIs) |
| ||||||||||||||
SERT (SRIs) |
| ||||||||||||||
VMATs |
| ||||||||||||||
Others |
| ||||||||||||||
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins |
This drug article relating to the nervous system is a stub. You can help Wikipedia by . |
- v
- t
Retrieved from ""
Categories:
- Drugs not assigned an ATC code
- Tertiary alcohols
- Stimulants
- GlaxoSmithKline brands
- Norepinephrine-dopamine reuptake inhibitors
- Morpholines
- Fluoroarenes
- Nervous system drug stubs
Hidden categories:
- Articles with changed ChemSpider identifier
- Articles with changed InChI identifier
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- All articles with unsourced statements
- Articles with unsourced statements from March 2016
- All stub articles